Safety of caplacizumab in patients without documented severe ADAMTS13 deficiency during the Hercules study


1 Istanbul University CAPA, Fatih/Istanbul, Turkey
2 Catholic University of Valencia and Hospital Doctor Peset Valencia, Valencia, Spain
3 Università degli Studi di Milano, Milan, Italy
4 National Institute for Health Research UCLH-UCL Biomedical Research Center, London, United Kingdom
5 The Ohio State University, Columbus, OH, United States
6 Saint-Antoine University Hospital, AP-HP, Paris, France
7 Bern University Hospital, University of Bern, Bern, Switzerland
8 Medical University of Vienna, Vienna, Austria
9 Duke University School of Medicine, Durham, NC, United States
10 St. Michael’s Hospital and University of Toronto, Toronto, ON, Canada
11 Ablynx, a Sanofi Company, Ghent, Belgium
12 Sanofi, Lisbon, Portugal
13 Sanofi, Diegem, Belgium

Objective: To describe the safety of caplacizumab in patients enrolled in HERCULES for whom the diagnosis of aTTP was not confirmed based on documented severe ADAMTS13 deficiency.

Methodology: In HERCULES (NCT02553317), ADAMTS13 was measured at study baseline (following initial TPE), weekly following cessation of daily TPE during the treatment period, and twice during the follow-up period. Data from patients for whom the diagnosis of aTTP was not confirmed based on documented ADAMTS13 levels <10% were extracted and analyzed descriptively for efficacy and safety outcomes, with a focus on bleeding events.

Results: Overall, 7 patients in the placebo group (9.6%) and 13 patients in the caplacizumab group (18.1%) had a baseline ADAMTS13 >10%; of these, 4 and 9 patients, respectively, had a prior medical history of aTTP and/or ADAMTS13 values <10% at other time points during the study. This left 3 patients in the placebo group and 4 patients in the caplacizumab group for whom the diagnosis of aTTP could not be confirmed based on subsequent ADAMTS13 values or prior medical history, suggesting a diagnosis other than aTTP. Baseline ADAMTS13 levels were >60% for all patients and remained well above 10% throughout the study period. Possible alternative diagnoses included pancreatitis-induced TTP in 2 patients. One patient was reported as having ‘thrombotic microangiopathy’ and discontinued study drug treatment after 4 days (but continued daily TPE). The fourth patient had a report of ‘megaloblastic anemia’ and ‘general adenopathies’ and was withdrawn from the study due to a ‘non-TTP diagnosis’ after 2 days. The patients who continued daily TPE achieved a platelet count of >150 x 10^9/L. Two patients experienced a moderate bleeding-related serious adverse event (SAE), 1 case of ‘gastric ulcer hemorrhage’ (considered unlikely related to study drug and recovered without intervention) and 1 case of epistaxis that led to study drug discontinuation (considered possibly related to study drug and recovered without intervention). Other mild bleeding-related non-serious adverse events (AEs) were reported in 1 patient: gingival bleeding (possibly related), ecchymosis (possibly related), and rectal hemorrhage (not/unlikely related). All events recovered spontaneously without intervention. Two other non-bleeding related SAEs were reported in 2 patients, both considered unrelated to study drug: 1 case of bacteremia and 1 case of cardiac tamponade.

Conclusion: The experience of caplacizumab in patients with a suspected non-aTTP diagnosis to date is limited, and no definite conclusion can be drawn. Bleeding-related AEs were reported in 3 of the 4 patients; however, the type, nature and manageability of these events appear similar to those reported in the other patients in the study. Data first presented at American Society of Hematology annual meeting, December 7–10, 2019. Study sponsored by Sanofi.

https://doi.org/10.1016/j.htct.2020.09.111

PP 49

Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura


1 Erciyes University, Kayseri, Turkey
2 Saint-Antoine University Hospital, AP-HP, Paris, France
3 National Institute for Health Research UCLH-UCL Biomedical Research Center, London, United Kingdom
4 Catholic University of Valencia and Hospital Doctor Peset Valencia, Valencia, Spain
5 Università degli Studi di Milano, Milan, Italy
6 The Ohio State University, Columbus, OH, United States
7 Bern University Hospital, University of Bern, Bern, Switzerland
8 Medical University of Vienna, Vienna, Austria
9 St. Michael’s Hospital and University of Toronto, Toronto, ON, Canada
10 Ablynx, a Sanofi Company, Zwijnaarde, Belgium
11 Sanofi, Diegem, Belgium
12 Sanofi, Lisbon, Portugal

Objective: To characterize the durability of platelet count responses in the HERCULES trial.
Methodology: In this post hoc analysis of the HERCULES (NCT02553317) intent-to-treat population (caplacizumab, n = 72; placebo, n = 73), we identified patients with a fast platelet count response (i.e., ≤3 days vs. >3 days) and described the exacerbation rate by treatment group. Time to durable platelet count response (defined as time to last daily TPE during the overall treatment period), time to complete remission (defined as platelet count >150 × 10^9/L and lactate dehydrogenase <1.5 × the upper limit of normal for >30 days after cessation of daily TPE), and recurrence-free survival (absence of exacerbation or relapse during the overall study period) were calculated.

Results: More than half of the patients in the HERCULES trial achieved an initial platelet count normalization within 3 days (caplacizumab, 56/72 [78%]; placebo, 43/73 [59%]). In patients with a fast platelet count response (ie, ≤3 days), the exacerbation rate was 3.6% (2/56) with caplacizumab and 44.2% (19/43) with placebo, suggesting that the rapid platelet count response was sustained with caplacizumab, whereas almost half of the fast responders in the placebo group subsequently exacerbated. In patients with time to platelet count response ≤3 days, the exacerbation rate was 6.7% (1/15) with caplacizumab and 30.0% (9/30) with placebo, confirming the durable response with caplacizumab. The exacerbation rate among placebo patients with platelet response >3 days remained high but was numerically lower compared with fast responders. Of the patients who experienced exacerbations, 90% (2/3 in the caplacizumab group and 26/28 in the placebo group) switched to open-label caplacizumab, which may have favored the outcomes of placebo patients. Despite this bias, the median (95% CI) time to durable response was 4.5 (4.4–4.6) days with caplacizumab and 10.5 (6.5–14.5) days with placebo; accordingly, the median (95% CI) time to complete remission was shorter in the caplacizumab group (40.0 [37.7–41.1] days) compared with placebo (44.2 [42.0–48.2] days). The analysis of overall recurrence-free survival during the entire study period demonstrated an early and sustained benefit for caplacizumab compared with placebo (44.2 [42.0–48.2] days). The analysis of overall recurrence-free survival during the entire study period demonstrated an early and sustained benefit for caplacizumab compared with placebo (44.2 [42.0–48.2] days). The analysis of overall recurrence-free survival during the entire study period demonstrated an early and sustained benefit for caplacizumab compared with placebo (44.2 [42.0–48.2] days). The analysis of overall recurrence-free survival during the entire study period demonstrated an early and sustained benefit for caplacizumab compared with placebo (44.2 [42.0–48.2] days). The analysis of overall recurrence-free survival during the entire study period demonstrated an early and sustained benefit for caplacizumab compared with placebo (44.2 [42.0–48.2] days).

Conclusion: Caplacizumab demonstrated a faster and sustained platelet count response compared with the placebo group, in which many fast responders subsequently had an exacerbation. Fast platelet count responses with caplacizumab were maintained and translated into clinically relevant improvements in time to complete remission and overall recurrence-free survival. Data first presented at EHA 2020 virtual meeting, June 11–21st. Study sponsored by Sanofi.

https://doi.org/10.1016/j.htct.2020.09.112

STEM CELL TRANSPLANT

PP 50

Transplant in aplastic anemia using combined G-CSF primed blood and bone marrow stem cells – a retrospective analysis

N. Ali, A. Butt*, B. Altaf, S. Adil, U. Shaikh

Aga Khan University Hospital, Karachi, Pakistan

Objective: Aplastic anemia is characterized by diminished or absent hematopoietic precursors in the bone marrow, most often due to injury to the pluripotent stem cell. In Pakistan, Aplastic Anemia is not uncommon and allogeneic hematopoietic stem cell transplant remains the only curative option in these patients. We aim to determine the transplant outcome of combined, G-CSF primed blood and bone marrow grafts in adult and pediatric patients with aplastic anemia.

Methodology: We retrospectively collected data of all transplant procedures performed from 2004–2019 at Aga Khan University Karachi, Pakistan. Variables analyzed included type of transplants, age, gender, type of stem cells used, conditioning regimens and overall survival for patients undergoing transplant in aplastic anemia.

Results: A total of 351 transplants were performed during the study period. Out of these, 239 were allogeneic transplants whereas 112 were autologous procedures. There were 254 males and 97 females. The main indications for allogeneic stem cell transplant were aplastic anemia (70), acute leukemia (58) and beta thalassemia major (40). Out of 70 patients with aplastic anemia, 52 were males and 18 were females. 38.6% percent of patients were from pediatric age group. The median age ± SD was 17.5 ± 9.4 years (range: 2–43 years). Cyclophosphamide/ATG was used as a conditioning regimen in 67 patients, while ATG/cyclophosphamide/fludarabine was used in 2. Haploidentical transplant was done in 1 patient. Twenty seven percent of patients underwent sex-mismatched procedures. In 52 patients, a combination of G-CSF primed blood and bone marrow stem cells were used. The mean CD34 count was 5.2 × 10^3/kg. GVHD prophylaxis was done with cyclosporine and methotrexate. All patients received standard infection prophylaxis. Engraftment was achieved in 75% of patients. The median day of myeloid engraftment was 15 (range 10–22 days). Chronic GVHD was present in 3 patients while 4 had acute GVHD. The overall survival was 71.2% (median duration of 80 months). The causes of mortality included gram-negative sepsis (5), graft versus host disease (4), graft failure (4), disseminated fungal infection (2), intracranial bleed (2), bleeding diathesis (2) and transplant associated microangiopathy (3).

Conclusion: Combination of blood and bone marrow stem cells results in early engraftment with decreased frequency of GVHD in aplastic anemia. The overall survival was comparable to international literature.

https://doi.org/10.1016/j.htct.2020.09.113